Search clinical trials for: Cyclophosphamide or Bendamustine

Total 9425 results

Fate Therapeutics

Terminated

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia

United States
Eagle Pharmaceuticals, Inc.

Completed

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

United States
SymBio Pharmaceuticals

Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

GIMEMA CLL0809 Study (BendOfa) (BendOfa)

Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines

Italy
Shandong Lanjin Pharmaceuticals Co.,Ltd

Unknown

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma by Clinical Course

China
Fate Therapeutics

Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Advanced Solid Tumor

United States
German Breast Group

Completed

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer (RiTa)

Metastatic Breast Cancer
Nevada Cancer Institute
GlaxoSmithKline; Cephalon

Withdrawn

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Chronic Lymphocytic Leukemia (CLL)

United States
Mayo Clinic

Completed

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Refractory Multiple Myeloma

United States
German CLL Study Group
Gilead Sciences; Novartis Pharmaceuticals

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Chronic Lymphocytic Leukemia

Germany
Samsung Medical Center

Unknown

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

Mantle Cell Lymphoma

Korea, Republic of
Fate Therapeutics

Recruiting

FT576 in Subjects With Multiple Myeloma

Multiple Myeloma | Myeloma

United States
Cephalon

Completed

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

Non-Hodgkin's Lymphoma

United States, Canada, Puerto Rico
Hoffmann-La Roche

Active, not recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, Australia, Spain, France
State Budgetary Healthcare Institution, National...

Unknown

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation (BeEAC-1)

Relapsed/Refractory Malignant Lymphomas

Russian Federation
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Lung Cancer

United States
French Innovative Leukemia Organisation
Mundipharma Pte Ltd.

Completed

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (BENTLY)

T-cell Lymphoma

France
WiSP Wissenschaftlicher Service Pharma GmbH
Mundipharma Research GmbH & Co KG; Klinikum Leverkusen gGmbH; ribosepharm GmbH

Completed

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Nevada Cancer Institute
GlaxoSmithKline; Cephalon

Terminated

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Chronic Lymphocytic Leukemia (CLL)

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Novartis Pharmaceuticals

Completed

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Lymphoma, Non-Hodgkin

United States
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). (BeEAM2010-01)

Bendamustine | Conditioning Therapy | Autologous Stem Cell Transplant | Aggressive Non Hodgkin's Lymphoma

Spain
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States
Fate Therapeutics

Recruiting

FT819 in Subjects With B-cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | Precursor B-Cell Acute Lymphoblastic Leukemia

United States
Lundbeck Canada Inc.

Completed

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia (BENDACT)

Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin's Lymphoma

Canada
Yale University

Withdrawn

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Hematopoietic/Lymphoid Cancer | Infectious Mononucleosis | PTLD | Lymphoid Tumor | Plasmacytic Hyperplasia PTLD | Florid Follicular Hyperplasia PTLD | Polymorphic PTLD | Monomorphic PTLD | Classical Hodgkin Lymphoma Type PTLD

United States
Kami Maddocks, MD
Pharmacyclics LLC.

Active, not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

China
Novartis Pharmaceuticals

Completed

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; Novartis; Cephalon

Completed

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

Diffuse Large B-Cell Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma (IIL INFL09)

Non-Hodgkin's Lymphoma | Indolent Non-follicular

Italy
UNC Lineberger Comprehensive Cancer Center
Cephalon

Completed

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell Lymphoma

United States
Cephalon

Completed

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States, Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Relapsed T-Cell Lymphoma | Refractory T-Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Comprehensive Cancer Network; Cephalon

Completed

Bendamustine and Bevacizumab for Advanced Cancers

Advanced Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Indolent B-Cell Non-Hodgkin's Lymphomas

China
St. Petersburg State Pavlov Medical University
N.N. Petrov National Medical Research Center of Oncology

Recruiting

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma (Prolgo-HL)

Hodgkin Lymphoma

Russian Federation
Sidney Kimmel Cancer Center at Thomas Jefferson...

Withdrawn

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma | Plasma Cell Leukemia

United States
NYU Langone Health
Millennium Pharmaceuticals, Inc.

Terminated

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Peter Moosmann
Kantonsspital Aarau

Completed

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Lymphoma, Non-Hodgkin
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Arbeitsgemeinschaft medikamentoese Tumortherapie
Mundipharma Pte Ltd.

Completed

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
University of Liverpool
GlaxoSmithKline; Chugai Pharma USA; Napp Pharmaceuticals Limited

Unknown

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (RIAltO)

Chronic Lymphocytic Leukaemia

United Kingdom
Latin American Cooperative Oncology Group
Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)

Recruiting

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer (NEOSAMBA)

Breast Cancer

Brazil
University of Giessen

Completed

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Marginal Zone Lymphomas | Non-Hodgkin Lymphomas | Follicular Lymphomas | Immunocytomas | Lymphocytic Lymphomas

Germany
Hoffmann-La Roche

Completed

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Spain
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma (NHL)

United States, Belgium, Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

Non-Hodgkin Lymphoma

China

Search clinical trials for: Cyclophosphamide or Bendamustine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations